Promegestone

Promegestone
Clinical data
Synonyms	R-5020; RU-5020
ATC code	G03DB07 (WHO) ;
Identifiers
	IUPAC name (8S,13S,14S,17S)-13,17-dimethyl-17-propionyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one;
CAS Number	34184-77-5;
PubChem CID	36709;
ChemSpider	33716;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C22H30O2
Molar mass	326.472 g/mol
3D model (JSmol)	Interactive image;
	SMILES CCC(=O)[C@]1(CC[C@@H]2[C@@]1(CCC3=C4CCC(=O)C=C4CC[C@@H]23)C)C;
	InChI InChI=1S/C22H30O2/c1-4-20(24)22(3)12-10-19-18-7-5-14-13-15(23)6-8-16(14)17(18)9-11-21(19,22)2/h13,18-19H,4-12H2,1-3H3/t18-,19+,21+,22-/m1/s1; Key:QFFCYTLOTYIJMR-XMGTWHOFSA-N;

Promegestone (INN) (brand name Surgestone), also known as 17α,21-dimethyl-19-nor-Δ⁴,⁹-pregnadiene-3,20-dione, is a 19-norprogesterone derivative and steroidal progestin which was introduced in 1983 and is marketed in France, Portugal, and Argentina.^[1]^[2]^[3]^[4] Indications include gynaecological conditions caused by luteal insufficiency, including premenopausal disorders, dysmenorrhea, and premenstrual syndrome.^[4] Unlike some other progestins, promegestone is devoid of androgenic properties.^[4]

In addition to its progestogenic properties, promegestone has also been found to act as a non-competitive antagonist of the nicotinic acetylcholine receptor.^[5]

References

↑ R.A. Hill; H.L.J. Makin; D.N. Kirk (23 May 1991). Dictionary of Steroids. CRC Press. pp. 759–. ISBN 978-0-412-27060-4. Unknown parameter |coauthors= ignored (help)
↑ William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia, 3rd Edition. Elsevier. pp. 2935–. ISBN 978-0-8155-1856-3.
↑ Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 883–. ISBN 978-3-88763-075-1.
↑ ^4.0 ^4.1 ^4.2 Cain (11 September 1984). ANNUAL REPORTS IN MED CHEMISTRY V19 PPR. Academic Press. pp. 323–. ISBN 978-0-08-058363-1.
↑ Blanton MP, Xie Y, Dangott LJ, Cohen JB (February 1999). "The steroid promegestone is a noncompetitive antagonist of the Torpedo nicotinic acetylcholine receptor that interacts with the lipid-protein interface". Mol. Pharmacol. 55 (2): 269–78. PMID 9927618.